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Impact of health insurance status on vaccination coverage 
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Abstract
Background—Underinsurance has been a barrier to vaccination among children. Information on 
vaccination among adults ≥18 years by insurance status is limited.
Purpose—To assess vaccination coverage among adults ≥18 years in the United States in 2012 
by health insurance status and access to care characteristics.
Methods—The 2012 NHIS data were analyzed in 2014 to estimate vaccination coverage among 
adults ≥18 years by health insurance status for 7 vaccines routinely recommended for use. For the 
non-influenza vaccination coverage estimates among adults ≥18 years, regular descriptive analysis 
was used. To better assess influenza vaccination coverage for the 2011–12 influenza season, 
coverage was reported by restricting to individuals interviewed during September 2011 through 
June 2012, and vaccinated during August 2011 through May 2012, using the Kaplan-Meier 
survival analysis procedure.
Results—Overall, for all age groups, vaccination coverage was lower among those without 
health insurance compared with those with health insurance for all except HepA vaccination. 
Influenza vaccination coverage among adults ≥18 years without or with health insurance was 
14.4% versus 44.3%, respectively, pneumococcal vaccination coverage among adults 18–64 years 
with high-risk conditions was 9.8% versus 23.0%, Td coverage (≥18 years) was 53.2% versus 
64.5%, Tdap coverage (≥18 years) was 8.4% versus 15.7%, HepA coverage (18–49 years) was 
16.6% versus 19.8%, HepB coverage (18–49 years) was 27.5% versus 38.0%, shingles coverage 
(≥60 years) was 6.1% versus 20.8%, and HPV coverage (female 18–26 years) was 20.9% versus 
39.8%. In addition, vaccination coverage differed by type of insurance, whether or not respondents 
had a regular physician, or number of physician contacts. Persons without health insurance were 
less likely than those with health insurance to be vaccinated for influenza (≥18 years), 
pneumococcal (18–64 years with high-risk conditions), tetanus (≥18 years), Tdap (≥18 years), and 
HPV (women 18–26 years) after adjusting for confounders.
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Conclusions—Overall, vaccination coverage among adults ≥18 years was lower among 
uninsured populations. Implementing effective strategies are needed to help improve vaccination 
coverage among adults ≥18 years, especially those without health insurance.
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National Health Interview Survey (NHIS)
Introduction
Overall, in 2011, the percentage of people without health insurance in the United States was 
15.7% (48.6 million) and the percentage was 17.8% (41.0 million) among adult populations.
1
 Among non-Hispanic whites, 11.1% (21.7 million) were uninsured in 2011, for non-
Hispanic blacks 19.5% (7.7 million), and for Hispanics 30.1% (5.8 million).1 Cost has been 
a barrier to receiving timely preventive medical care. The relationship between health 
insurance and vaccination coverage among childhood and adolescent populations has been 
widely studied.2–5 Information regarding some adult vaccinations by health insurance status 
was documented previously.6–11
Vaccination is the most effective strategy for preventing vaccine-preventable diseases and 
their complications. Adult vaccination coverage, however, remains low for most routinely 
recommended vaccines and well below Healthy People 2020 targets.12–15 The adult 
immunization schedule,16 updated annually by the Advisory Committee on Immunization 
Practices (ACIP), provides current recommendations for vaccinating adults. Influenza 
vaccination is recommended for all adults each year; other vaccinations recommended for 
adults target different populations based on age, health conditions, behavioral risk factors, 
occupation, travel, and other indications.16, 17
This study uses data from the 2012 National Health Interview Survey (NHIS) to examine 
associations of routinely recommended adult vaccinations (influenza, pneumococcal 
[PPSV], tetanus toxoid–containing vaccines including tetanus and diphtheria toxoid [Td], 
tetanus, diphtheria and acellular pertussis [Tdap], hepatitis A [HepA], hepatitis B [HepB], 
herpes zoster [shingles], and human papillomavirus [HPV]) with insurance status, having a 
primary physician, seeing a provider during the previous year, and select demographic 
characteristics.
Methods
The 2012 NHIS were analyzed in 2014 (The 2013 data became available after the 
manuscript was submitted). The NHIS is a multistage sampling survey, which collects health 
information on the U.S. civilian, non-institutionalized population.18 In the sample adult core, 
questions about receipt of recommended vaccinations for adults were asked of one randomly 
selected adult within each family in the household. In 2012, the final response rate for the 
sample adult core was 61.2%.18
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Vaccination coverage for influenza, PPSV, Td, HepA, HepB, shingles, and HPV vaccines 
were assessed from coded survey questions on receipt of these vaccines (Respondents were 
asked whether they have ever received specific vaccinations or not except for influenza 
vaccination which seasonal vaccination were asked and assessed).18 To determine Tdap 
vaccination status, respondents were asked “Have you received a tetanus shot in the past 10 
years?” Respondents who answered “yes” were asked “Was your most recent tetanus shot 
given in 2005 or later?” An affirmative answer to this question prompted another question, 
“Did the doctor tell you the vaccine included the pertussis or whooping cough vaccine?” 
Respondents without “yes” or “no” responses for the above three questions were excluded 
from the assessment of Tdap vaccination.
Covariates from coded survey questions were selected to measure associations between 
vaccination coverage and health insurance status (yes, no), health insurance type (public 
only, private (including some people with both private and public insurances), none), regular 
physician status (yes, no), number of provider visits during the prior year (0, 1–3, 4–9, 10+), 
and race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic Asian, and other 
races including American Indian/Alaska Native and persons reporting multiple races). 
Demographic (e.g., marital status) and access to care variables (e.g., health insurance) reflect 
the status as of the time of survey. HepA vaccination was assessed among those traveling to 
countries of high or intermediate endemicity. Pneumococcal vaccination was assessed 
among all persons 65 and older and adults 18–64 with high-risk conditions. Persons were 
considered at high risk for pneumococcal disease if they had ever been told by a doctor or 
other health professional that they had diabetes, emphysema, chronic obstructive pulmonary 
disease, coronary heart disease, angina, heart attack, or other heart condition; had a 
diagnosis of cancer during the previous 12 months (excluding nonmelanoma skin cancer); 
had ever been told by a doctor or other health professional that they had lymphoma, 
leukemia, or blood cancer; had been told by a doctor or other health professional that they 
had chronic bronchitis or weak or failing kidneys during the preceding 12 months; had an 
asthma episode or attack during the preceding 12 months; or were current smokers. Poverty 
status was defined using 2012 poverty thresholds published by the U.S. Census Bureau with 
below poverty defined as a total family income of <$23,492 for a family of four.19
SUDAAN statistical software was used to calculate point estimates and 95% confidence 
intervals (CIs) of vaccination coverage.20 For the non-influenza adult vaccination coverage 
estimates, regular descriptive analysis was used. To better assess influenza vaccination 
coverage for the 2011–12 influenza season, coverage was reported by restrictingd to 
individuals interviewed during September 2011 through June 2012 and vaccinated during 
August 2011 through May 2012 using the Kaplan-Meier survival analysis procedure. 
Vaccination month was used to define the “event” variable and interview date to define the 
“censoring” variable of the Kaplan Meier procedure. The Kaplan-Meier has advantages for 
season-specific influenza estimates over other approaches, such as using a full calendar year 
of data which provides annual estimates representing incomplete estimates for up to three 
influenza seasons, or restricting estimates based on interviews conducted in the 
postvaccination period (e.g. March-June) which does not use all relevant data.21. The 
Kaplan-Meier approach allows us to use all relevant data to maximize precision and to use 
data collected during the vaccination period that likely has more accurate recall of 
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vaccinations.21. Estimates were weighted to the adult civilian population of the United 
States. Chi-square test was used to test coverage difference within or between variables 
assessed. Statistical significance was defined as p<0.05 (p value is two-sided). Influenza, 
PPSV, and HepB coverage differences by health insurance status between 2001 and 2012 
were assessed (information regarding other vaccines were not collected in the 2001 NHIS). 
Wide differences by insurance status (with versus without insurance) may indicate more 
strength of association between insurance status. To assess adjusted vaccination coverage 
and adjusted prevalence ratios for each selected vaccination, we used logistic regression and 
predicted marginal modeling comparing persons with health insurance and those without 
health insurance controlling for age, gender, race/ethnicity, marital status, education, 
employment status, poverty level, health insurance, number of doctor visits in the past year, 
whether the respondent had a usual place of health care, self-reported health status, and 
region of residence. The NHIS was approved by Research Ethics Review Board (the ERB 
number is 2009-16) of the National Center for Health Statistics, Centers for Disease Control 
and Prevention.
Results
Characteristics of the study population are shown in Table 1.
Overall, vaccination coverage was significantly lower among adults without health insurance 
compared with those with health insurance, except for overall hepatitis A vaccination and 
HepB vaccination of persons ≥18 years with diabetes (Table 2): influenza coverage, adults 
≥18 years (14.4% versus 44.3%), PPSV, 18–64 years with high-risk conditions (9.8% versus 
23.0%), Td, ≥18 years (53.2% versus 64.5%), Tdap, ≥18 years (8.4% versus 15.7%), HepA 
(≥ 2 doses), 18–49 years traveling to countries of high or intermediate endemicity (16.6% 
versus 19.8%), HepB (≥ 3 doses), adults 18–49 years (27.5% versus 38.0%), shingles, adults 
≥60 years (6.1% versus 20.8%), and HPV, females 18–26 years (20.9% versus 39.8%) 
(p<0.05) (Table 2). Coverage was lower for these vaccinations among those with no 
insurance compared with those who reported either public or private health insurance. For 
influenza, pneumococcal, shingles, and HPV vaccination, coverage was two to three times 
higher among those with health insurance compared with those without insurance (Table 2).
Adult vaccination coverage differed by type of health insurance. Vaccination coverage was 
significantly higher among adults with private health insurance compared with those 
reporting public health insurance for pneumococcal vaccination among adults ≥65 years, 
tetanus vaccination among adults ≥18 years, Tdap vaccination among adults ≥18 years, 
HepB vaccination among adults 18–49 years and adults ≥18 years with diabetes, shingles 
vaccination among adults ≥60 years, and HPV vaccination among women 18–26 years 
(p<0.05) but lower for influenza vaccination among adults ≥18 years, pneumococcal 
vaccination among adults 18–64 years with high-risk conditions, and HepA vaccination 
among adults 18–49 years (p<0.05) (Table 2).
Generally, those with a regular physician were more likely to report having received 
recommended vaccinations than those who did not have a regular physician whether or not 
they had or did not have health insurance. Among adults with health insurance, coverage 
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was significantly higher among those who reported having a regular physician compared 
with those who did not have a regular physician, except for HepA vaccination among 
travelers. Among adults without health insurance, except for HepA vaccination among 
travelers and HPV vaccination among females 18–26 years, coverage was significantly 
higher among adults who had a regular physician compared to those who did not have a 
regular physician (Table 3).
With a few exceptions (HepA vaccination among travelers, HepB vaccination among adults 
with diabetes, and HPV vaccination among females 18–26 years) vaccination coverage was 
significantly higher among those reporting one or more physician contacts in the past year 
compared with those who had not visited a physician in the past year whether or not they 
had or did not have health insurance (Table 4). Additionally, vaccination coverage increased 
as the number of physician contacts increased (Table 4). Among adults who had health 
insurance and 10 or more physician contacts within the past year, 28.4%–80.4% reported not 
receiving recommended vaccinations (not receiving tetanus vaccination, 28.4%; PPSV [≥65 
years], 30.2%; influenza, 41.1%; PPSV [high-risk, 18–64 years], 61.0%; HPV [females, 18–
26 years], 61.4%; HepA [travelers, 18–49 years], 72%; HepB [≥18 years with diabetes], 
76.5%; shingles, 76.9%; and, Tdap, 80.4% (Table 4).
Influenza and PPSV vaccination coverage among adults ≥65 years were usually higher 
compared with coverage among adults 18–64 years but Td, Tdap, and HepB coverage 
among adults ≥65 years were usually lower compared with coverage among adults 18–64 
years (Table 2–Table 4). Shingles vaccination coverage among adults ≥65 years were usually 
higher compared with coverage among adults 60–64 years (Table 2–Table 4). Additionally, 
for influenza, pneumococcal, and HepB vaccinations, majority of coverage differences by 
health insurance status (with insurance versus without insurance) were smaller in 2001 
compared with coverage differences by health insurance status in 2012 (Table 5).
Persons without health insurance were significantly less likely than those with health 
insurance to be vaccinated for influenza (≥18 years), pneumococcal (18–64 years with high-
risk conditions), tetanus (≥18 years), Tdap (≥18 years), and HPV (women 18–26 years) after 
adjusting for confounders (Table 6). The difference in adjusted vaccination coverage 
between persons with health insurance and persons without health insurance ranged from 
−0.2% (HepA vaccination among travelers 18–49 years) to 10.9% (influenza vaccination 
among persons ≥18 years) (Table 6).
Discussion
This is the first comprehensive assessment of vaccination coverage by health insurance 
status among adult populations in the United States. Such information is important for 
understanding factors that contribute to disparities in vaccination coverage and 
implementing strategies to improve vaccination coverage.2–5, 22–28 Most respondents (83%) 
in this study indicated having some type of health insurance. Having health insurance was 
associated with a greater likelihood of having received recommended vaccinations even after 
adjusting for confounders for influenza, pneumococcal, tetanus, and Tdap. For influenza, 
pneumococcal, shingles, and HPV vaccination, coverage was two to three times higher 
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among those with health insurance compared with those without insurance. Wider coverage 
differences by insurance status (with versus without insurance) in 2012 compared with 2001 
may indicate a greater strength of association between health insurance and vaccination in 
2012 compared with 2001. Additionally, after controlling demographic and access to care 
variables based on our multivariable analysis, coverage might increase up to 11 percentage 
points if those without health insurance had health insurance.
The type of health insurance indicated by respondents had a significant association with 
vaccination coverage. In this study, vaccination coverage was generally higher among adults 
with private health insurance compared with those reporting public health insurance. Studies 
on insurance status and vaccination in children have reported similar findings.2, 3, 29, 30 The 
factors contributing to vaccination levels by type of health insurance are not well 
understood. In one study, persons with private health insurance declined during 1999 
through 2011, ranging from 67% to 74% during 1999 through 2008, and 64% during 2009 
through 2011.1 This downward shift in private insurance coverage could have a negative 
impact on most adult vaccination coverage. Better understanding is needed of factors 
influencing vaccination by type of health insurance.
For those ≥65 years, Medicare covers some vaccinations. Medicare Part B covers influenza, 
PPSV, and HepB (if people are at high risk). Part B also covers other vaccinations only if 
people have been exposed to a dangerous virus or disease (e.g., if people step on a rusty nail 
(acute wound)), Medicare will cover a Td shot). All vaccines other than influenza, PPSV, 
and HepB are covered under Medicare Part D including shingles. Medicare Part D plan pays 
for the vaccination itself and for doctor or other health care provider who give people the 
shot (administration). Those Medicare benefits may remove financial barriers to some 
vaccinations for those ≥65 years and help improve vaccination coverage among senior 
adults.31
Vaccination coverage for three vaccines in this report that are included in Healthy People 
2020 (influenza, pneumococcal, and herpes zoster) were well below the respective target 
levels of 70% for influenza vaccination among adults ≥18 years, 60% for pneumococcal 
vaccination among adults 18–64 years with high-risk conditions, 90% for pneumococcal 
vaccination among adults ≥65 years, and 30% for shingles vaccination among adults ≥60 
years, even among those with health insurance.14, 15 Substantial improvement in vaccination 
coverage among adult populations, especially among those without health insurance, will be 
needed to achieve Healthy People 2020 targets.
Removing cost barriers to adult vaccination might improve coverage.23–25 The federal 
Immunization Grant Program supports the immunization infrastructure to deliver vaccines to 
underinsured children and, as funding permits, to uninsured and underinsured adults.32 The 
vaccine manufacturer of HepA, HepB, shingles, and HPV vaccines has implemented a 
program, the Merck Vaccine Patient Assistance Program, which provides free vaccines to all 
adults who are uninsured and poor (household income less than $44,680 for individuals, 
$60,520 for couples, or $92,200 for a family of four).33 Additionally, this manufacturer 
sometimes makes exceptions based on individual circumstances in special circumstances of 
financial or medical hardship.33 Programs like this might help improve vaccination coverage 
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among uninsured and poor adult populations. Federal, state, and local partners should 
continue to build support for adult vaccination and identify other strategies to remove cost 
barriers for uninsured populations.
Generally, those with a regular physician were more likely to report having received 
recommended vaccinations than those who did not have a regular physician whether or not 
they had or did not have health insurance and vaccination coverage generally increased as 
the number of physician contacts increased. This observation from our study suggests that 
increased number of physician contacts might have facilitated opportunities to be reminded 
of the need for vaccinations and discussions about vaccinations that were indicated and a 
recommendation and decision to vaccinate. These findings are also consistent with previous 
reports indicating that persons who have a usual place for health care or medical home and 
who seek medical care one or more times during the year are more likely to be vaccinated 
and receive other preventive services than those without a usual place for health care.30, 34 
Studies have shown that healthcare provider recommendations for vaccination are strongly 
associated with adult vaccination coverage.35–38 Having a regular physician and routine 
physician contact can provide important opportunities for providers to educate their patients 
about vaccine-preventable diseases, recommend, and offer vaccination.23, 35–37 Routine 
patient reminder and recall, expanded access in health care settings, reduced patient’s out-of-
pocket costs, provider reminder, standing orders, and provider assessment and feedback 
should be incorporated into routine clinical care of adults.39–41
The findings in this report are subject to limitations. First, adult vaccination coverage was 
self-reported and therefore might be subject to recall bias. However, self-reported influenza 
and PPSV vaccination status among adults have been shown to be fairly sensitive and 
specific.42–46 Adult self-reported vaccination status has also been shown to be sensitive for 
tetanus, HepA, HepB, HPV, and shingles vaccination and specific for vaccination with all 
these vaccines, except for tetanus vaccination.46 Second, NHIS response rates were 60%–
70%, and it is possible that nonresponse bias may have remained after weighting 
adjustments. Third, self-reported vaccination might be subject to social desirability bias. 
Third, statistical tests for estimates were conducted with one group as referent and we did 
not do multiple comparisons. Finally, other factors like cultural, religious, vaccine safety 
concerns, state immunization intervention programs, lots of other factors may also affect 
vaccination coverage and NHIS did not collect those kinds of information.
Adult vaccination coverage is low overall and especially low for those without health 
insurance. Any comprehensive strategy needs to be tailored to the needs of the health care 
institution to improve coverage among general adults and adults without health insurance.
39, 40
 The Patient Protection and Affordable Care Act (ACA) requires that certain clinical 
preventive services including all ACIP recommended vaccines be provided without cost 
sharing in Medicare Part B benefits and by newly qualified private and public health plans. 
The ACA also encourages state Medicaid programs to provide selected clinical preventive 
services with no cost-sharing.47 Beginning in 2013, state Medicaid programs that eliminate 
cost sharing for these preventive services may receive enhanced federal matching funds for 
them.47,48 The expanded enrollment in public and private insurance programs expected from 
provisions of the ACA might improve access to health care services (including vaccination) 
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for persons who were previously without health insurance. Other provisions of the ACA that 
create incentives for primary care, including increased payments for primary care services 
provided by primary care doctors, and coverage without cost sharing 49 for vaccines 
recommended by the ACIP, should also help to improve adult vaccination coverage. 
Additionally, to improve vaccination coverage, routine patient reminder and recall, expanded 
access in health care settings, reduced patient’s out-of-pocket costs, provider reminder, 
standing orders, and provider assessment and feedback should be incorporated into routine 
clinical care of adults.39–41
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us
 v
a
cc
in
at
io
n 
(≥
 1 
do
se
)
 
18
–2
6 
M
al
e
-
-
d
R
ef
er
en
ce
-
-
d
-
-
d
-
-
d
 
18
–2
6 
Fe
m
al
e
34
.9
 (3
0.9
, 3
9.2
)
R
ef
er
en
ce
29
.5
 (2
2.6
, 3
7.5
)
0.
8 
(0.
6, 
1.1
)
5.
4
N
ot
e:
 
B
ol
df
ac
e 
in
di
ca
te
s s
ig
ni
fic
an
ce
.
A
bb
re
v
ia
tio
ns
: C
I=
Co
nf
id
en
ce
 in
te
rv
al
.
a M
ul
tiv
ar
ia
bl
e 
lo
gi
sti
c 
m
od
el
 w
as
 c
o
n
du
ct
ed
 to
 g
et
 a
dju
ste
d v
ac
ci
na
tio
n 
co
v
er
ag
e 
(ad
jus
ted
 fo
r a
ge
, g
en
de
r, r
ac
e/
et
hn
ic
ity
,
 
m
ar
ita
l s
ta
tu
s, 
ed
uc
at
io
n,
 e
m
pl
oy
m
en
t s
ta
tu
s, 
po
v
er
ty
 le
v
el
, n
um
be
r o
f p
hy
sic
ia
n 
co
n
ta
ct
s 
in
 th
e 
pa
st 
ye
ar
,
 
u
su
al
 so
ur
ce
 o
f c
ar
e,
 se
lf-
re
po
rte
d 
he
al
th
 st
at
us
, U
S.
 b
or
n 
sta
tu
s, 
re
gi
on
 o
f r
es
id
en
ce
).
b A
dju
ste
d v
ac
ci
na
tio
n 
co
v
er
ag
e 
am
on
g 
th
os
e 
w
ith
 h
ea
lth
 in
su
ra
nc
e 
m
in
us
 a
dju
ste
d v
ac
ci
na
tio
n 
co
v
er
ag
e 
am
on
g 
th
os
e 
w
ith
ou
t h
ea
lth
 in
su
ra
nc
e.
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c I
nf
lu
en
za
 v
ac
ci
na
tio
n 
co
v
er
ag
e 
es
tim
at
es
 a
re
 b
as
ed
 o
n 
in
te
rv
ie
w
s 
co
n
du
ct
ed
 d
ur
in
g 
Se
pt
em
be
r 2
01
1 
th
ro
ug
h 
Ju
ne
 2
01
2,
 a
nd
 v
ac
ci
na
tio
n 
re
ce
iv
ed
 d
ur
in
g 
th
e 
pa
st 
12
 m
on
th
s.
d N
ot
 e
no
ug
h 
sa
m
pl
e 
siz
e 
to
 ru
n 
ad
jus
ted
 m
od
els
.
*
p 
< 
0.
05
.
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